京新药业：公司LP（a）机制降脂新药目前处于临床I期，对外授权工作在进展中

Core Viewpoint - The company is currently in the clinical I phase for its LP(a) lowering drug, and the external licensing work is progressing, with updates to be provided through official announcements [1] Group 1 - An investor inquired about the progress of the company's LP(a) lowering drug BD business, expressing concerns about the perceived slow efficiency [1] - The company confirmed that the LP(a) lowering drug is in the clinical I phase and that the external licensing efforts are ongoing [1]